Published in J Neuroimmunol on February 15, 2009
HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology (2010) 2.29
Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann Neurol (2010) 1.17
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (2011) 1.11
Role of HDAC3 on p53 expression and apoptosis in T cells of patients with multiple sclerosis. PLoS One (2011) 0.97
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One (2013) 0.92
Humoral Responses to Diverse Autoimmune Disease-Associated Antigens in Multiple Sclerosis. PLoS One (2015) 0.87
Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. Neurol Neuroimmunol Neuroinflamm (2016) 0.85
Host genetics of Epstein-Barr virus infection, latency and disease. Rev Med Virol (2014) 0.84
Epstein-Barr virus antibodies in serum and DNA load in saliva are not associated with radiological or clinical disease activity in patients with early multiple sclerosis. PLoS One (2017) 0.75
Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med (2006) 6.25
MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology (2014) 3.27
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc (2006) 2.58
Clinical features and viral serologies in children with multiple sclerosis: a multinational observational study. Lancet Neurol (2007) 1.88
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol (2004) 1.82
Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change. J Neurol Sci (2005) 1.76
Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol (2006) 1.76
Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. J Neurol Neurosurg Psychiatry (2013) 1.69
Multiple sclerosis therapies in pediatric patients with refractory multiple sclerosis. Arch Neurol (2010) 1.61
Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients. J Neurol Neurosurg Psychiatry (2010) 1.59
Short-term brain atrophy changes in relapsing-remitting multiple sclerosis. J Neurol Sci (2004) 1.54
Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2014) 1.54
Thalamic involvement in multiple sclerosis: a diffusion-weighted magnetic resonance imaging study. J Neuroimaging (2003) 1.51
Basal ganglia, thalamus and neocortical atrophy predicting slowed cognitive processing in multiple sclerosis. J Neurol (2011) 1.51
Information-theoretic metrics for visualizing gene-environment interactions. Am J Hum Genet (2007) 1.47
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. J Neuroimmunol (2012) 1.46
Cerebellar mutism in pediatric acute disseminated encephalomyelitis. Pediatr Neurol (2010) 1.45
Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 1.44
Changes of cine cerebrospinal fluid dynamics in patients with multiple sclerosis treated with percutaneous transluminal angioplasty: a case-control study. J Vasc Interv Radiol (2013) 1.43
The incidence of amyotrophic lateral sclerosis in Friuli Venezia Giulia, Italy, from 2002 to 2009: a retrospective population-based study. Neuroepidemiology (2013) 1.43
Semantic integration to identify overlapping functional modules in protein interaction networks. BMC Bioinformatics (2007) 1.43
Retinal nerve fiber layer thickness is associated with brain MRI outcomes in multiple sclerosis. J Neurol Sci (2007) 1.39
Reliable screening for neuropsychological impairment in multiple sclerosis. Mult Scler (2004) 1.38
Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology (2006) 1.33
BioStar models of clinical and genomic data for biomedical data warehouse design. Int J Bioinform Res Appl (2005) 1.28
Risk of bone loss in men with multiple sclerosis. Mult Scler (2004) 1.27
Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study. Neuroimage (2011) 1.27
A novel functional module detection algorithm for protein-protein interaction networks. Algorithms Mol Biol (2006) 1.25
AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environmental associations with complex phenotypes. Genetics (2008) 1.24
Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol (2006) 1.23
Genomic effects of IFN-beta in multiple sclerosis patients. J Immunol (2003) 1.18
Use of MR venography for characterization of the extracranial venous system in patients with multiple sclerosis and healthy control subjects. Radiology (2010) 1.18
The relationship between whole brain volume and disability in multiple sclerosis: a comparison of normalized gray vs. white matter with misclassification correction. Neuroimage (2005) 1.16
Unemployment in multiple sclerosis: the contribution of personality and disease. Mult Scler (2011) 1.14
Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. J Neuroinflammation (2011) 1.11
The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc (2009) 1.10
Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline. Clin Neuropsychol (2010) 1.10
Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol (2008) 1.07
VizStruct: exploratory visualization for gene expression profiling. Bioinformatics (2004) 1.06
Validity of the Wisconsin Card Sorting and Delis-Kaplan Executive Function System (DKEFS) Sorting Tests in multiple sclerosis. J Clin Exp Neuropsychol (2007) 1.05
Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network. J Child Neurol (2012) 1.04
Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids (2005) 1.04
A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta-1a. J Neurol Sci (2003) 1.03
Validity of the California Verbal Learning Test-II in multiple sclerosis. Clin Neuropsychol (2009) 1.02
Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem (2010) 1.01
Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: a case control study. J Magn Reson Imaging (2012) 1.00
An information theoretic approach for analyzing temporal patterns of gene expression. Bioinformatics (2003) 1.00
Osteopontin gene haplotypes correlate with multiple sclerosis development and progression. J Neuroimmunol (2005) 0.99
Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler (2007) 0.99
Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci (2010) 0.99
Immune cell BDNF secretion is associated with white matter volume in multiple sclerosis. J Neuroimmunol (2007) 0.98
Nontraumatic headache in the Emergency Department: a survey in the province of Trieste. J Headache Pain (2005) 0.97
Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. BMC Neurol (2011) 0.96
Prediction of longitudinal brain atrophy in multiple sclerosis by gray matter magnetic resonance imaging T2 hypointensity. Arch Neurol (2005) 0.96
Chronic cerebrospinal venous insufficiency in multiple sclerosis: diagnostic, pathogenetic, clinical and treatment perspectives. Expert Rev Neurother (2011) 0.96
Bortezomib arrests the proliferation of hepatocellular carcinoma cells HepG2 and JHH6 by differentially affecting E2F1, p21 and p27 levels. Biochimie (2008) 0.96
Sex differences in in vitro pro-inflammatory cytokine production from peripheral blood of multiple sclerosis patients. J Neurol Sci (2003) 0.96
Cine cerebrospinal fluid imaging in multiple sclerosis. J Magn Reson Imaging (2012) 0.96
Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose. J Mol Med (Berl) (2007) 0.95
Comparison of intravascular ultrasound with conventional venography for detection of extracranial venous abnormalities indicative of chronic cerebrospinal venous insufficiency. J Vasc Interv Radiol (2013) 0.94
Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. AJNR Am J Neuroradiol (2004) 0.94
Disability progression in a clinical trial of relapsing-remitting multiple sclerosis: eight-year follow-up. Arch Neurol (2010) 0.94
Regional lobar atrophy predicts memory impairment in multiple sclerosis. AJNR Am J Neuroradiol (2005) 0.94
The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study. Neuroepidemiology (2003) 0.94
Information-theoretic gene-gene and gene-environment interaction analysis of quantitative traits. BMC Genomics (2009) 0.93
Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet (2007) 0.93
Independent contributions of cortical gray matter atrophy and ventricle enlargement for predicting neuropsychological impairment in multiple sclerosis. Neuroimage (2007) 0.93
Environmental factors associated with disease progression after the first demyelinating event: results from the multi-center SET study. PLoS One (2013) 0.92
Comparison of information-theoretic to statistical methods for gene-gene interactions in the presence of genetic heterogeneity. BMC Genomics (2010) 0.92
Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis. J Neurol Sci (2011) 0.92
The interaction index, a novel information-theoretic metric for prioritizing interacting genetic variations and environmental factors. Eur J Hum Genet (2009) 0.92
Platelet production and destruction in liver cirrhosis. J Hepatol (2010) 0.92
Sexual dysfunction in multiple sclerosis: a MRI, neurophysiological and urodynamic study. J Neurol Sci (2003) 0.91
A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord (2010) 0.91
HLA-DRB1*1501, -DQB1*0301, -DQB1*0302, -DQB1*0602, and -DQB1*0603 alleles are associated with more severe disease outcome on MRI in patients with multiple sclerosis. Int Rev Neurobiol (2007) 0.91